Data show that DNL343 is generally well-tolerated at doses that demonstrate robust inhibition of biomarkers associated with the integrated stress response (ISR)Clinical pharmacokinetic and ISR ...

Denali to present results from Phase 1 healthy volunteer study of EIF2B activator DNL343Sanofi to present Phase 2 study plans in ALS for RIPK1 inhibitor SAR443820Denali to host analyst and ...

First, simple measurements of eIF2B GEF activity in samples from patient-derived cells do not appear to be a suitable parameter for the general diagnosis of VWM, in contrast with recent ...

DNL343 is a novel small molecule ALS therapeutic candidate that targets eIF2B, a central regulator of the integrated stress response.

Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial ...

DNL343 (EIF2B Activator) for ALS and other neurodegenerative diseases Denali submitted a CTA in early December 2019 for DNL343, a small molecule brain-penetrant activator of EIF2B.

Mutations in two different subunits of the translation initiation factor eIF2B are found in patients with a severe neurological disorder.

Vanishing white matter disease (VWM) is a rare and progressive leukoencephalopathy caused by loss-of-function mutations, in a recessive pattern of inheritance, in any of the genes encoding eIF2B, a ...

--Denali Therapeutics Inc., a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for the treatment of neurodegenerative and ...

DNL343 is designed to activate eIF2B and thereby restore protein synthesis, disperse TDP-43 aggregates, and improve neuronal survival.